Source: Annual Congress 2005 - News about pulmonary embolism
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Romaszkiewicz, J. Lewczuk, P. Piszko, K. Wrabec (Wrocaw, Poland). Newly diagnosed patients with chronic thromboembolic pulmonary hypertension and PASP<50 mmHg. Do they need pulmonary endarterectomy?. Eur Respir J 2005; 26: Suppl. 49, 4452

Member's Comments

No comment yet.

Related content which might interest you: Surgical and post-operative treatment of chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2009; 19: 64-67 Year: 2010 Medical treatment in persistent pulmonary hypertension after pulmonary thrombendarterectomy in patients with chronic thrombembolic pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 364s Year: 2006 Pulmonary endarterectomy: the potentially curative treatment for patients with chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2015; 24: 263-271 Year: 2015 The course of chronic thromboembolic pulmonary hypertension (CTEPH) in anticoagulated patients not eligible for pulmonary endarterectomy Source: Eur Respir J 2002; 20: Suppl. 38, 237s Year: 2002 A 1-year evolution of pulmonary artery pressure in the patients treated with various therapeutic methods after acute pulmonary embolism (PE). Its impact on the chronic thromboembolic pulmonary hypertension (CTEPH) development Source: Eur Respir J 2003; 22: Suppl. 45, 221s Year: 2003 ERS statement on chronic thromboembolic pulmonary hypertension Source: ERS webinar 2021: ERS statement on chronic thromboembolic pulmonary hypertension Year: 2021 Chronic thromboembolic pulmonary hypertension Source: Eur Respir Mon 2012; 57: 108-118 Year: 2012 Comparison of clinical characteristics in patients with pulmonary arterial hypertension and inoperable chronic thromboembolic pulmonary hypertension Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease Year: 2008 Pulmonary angioplasty vs exclusive medical treatment in inoperable chronic thromboembolic hypertension–initial outcomes from a pulmonary hypertension centre Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020 Challenging cases in PH Source: Eur Respir Rev 2008; 17: 19-23 Year: 2007 Risk factors for chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2012; 21: 27-31 Year: 2012 Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2019 – Haemodynamics and chronic thromboembolic pulmonary hypertension Year: 2019 Incidence and outcomes of haemoptysis in patients with operable and non-operable chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016 Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020 Year: 2020 Pulmonary function in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study Source: Eur Respir J 2006; 28: 138-143 Year: 2006 Frequency of chronic thromboembolic pulmonary hypertension screening after pulmonary embolism in cancer patients. Source: International Congress 2018 – Pulmonary embolism: long-term sequelae and advances in therapies Year: 2018 Bosentan improves 6-minutes-walk-test in patients with inoperable chronic thrombo-embolic pulmonary hypertension (iCTEPH) Source: Eur Respir J 2005; 26: Suppl. 49, 272s Year: 2005